/
RSS Feed
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition. But it now looks as though MYC could be a viable target for cancer drugs. A phase one study of a “pan-MYC inhibitor” OMO 103 has made promising findings in both safety and efficacy according to a findings given to the 2022 EORTC-NCI-AACR symposium.
First author of the study, Elena Garralda MD, Head of Early Drug Development Unit at Vall d’Hebron Hospital in Barcelona gave the Audio Journal of Oncology’s Peter Goodwin the details:
